BMO Capital Markets Increases UiPath (NYSE:PATH) Price Target to $28.00

UiPath (NYSE:PATH) had its price objective hoisted by stock analysts at BMO Capital Markets from $24.00 to $28.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “market perform” rating on the healthcare company’s stock. BMO Capital Markets’ price objective suggests a potential upside of 21.40% from the company’s current price.

Several other research analysts have also commented on the stock. Evercore ISI upped their price objective on shares of UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a report on Thursday. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $22.00 to $28.00 in a research note on Thursday. William Blair began coverage on shares of UiPath in a research note on Tuesday, January 2nd. They issued an “outperform” rating for the company. Wells Fargo & Company increased their price target on shares of UiPath from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, December 1st. Finally, TD Cowen increased their price target on shares of UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. Nine research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, UiPath presently has an average rating of “Hold” and a consensus price target of $27.13.

UiPath Trading Up 1.4 %

NYSE PATH traded up $0.32 during trading on Thursday, hitting $23.07. The company had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a one year low of $12.38 and a one year high of $27.87. The company has a market cap of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The company’s fifty day moving average is $23.52 and its 200-day moving average is $20.70.

Insider Activity

In other news, CFO Ashim Gupta sold 70,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Ashim Gupta sold 70,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now directly owns 429,418 shares in the company, valued at approximately $9,928,144.16. The disclosure for this sale can be found here. Insiders have sold a total of 411,000 shares of company stock valued at $9,418,670 in the last 90 days. 31.03% of the stock is currently owned by insiders.

Hedge Funds Weigh In On UiPath

Institutional investors and hedge funds have recently made changes to their positions in the business. Royal London Asset Management Ltd. boosted its holdings in shares of UiPath by 5.9% in the third quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock worth $2,388,000 after buying an additional 7,742 shares during the last quarter. Barclays PLC boosted its holdings in shares of UiPath by 55.2% in the second quarter. Barclays PLC now owns 968,036 shares of the healthcare company’s stock worth $16,039,000 after buying an additional 344,499 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in shares of UiPath in the third quarter worth approximately $203,000. Invesco Ltd. boosted its holdings in shares of UiPath by 2.8% in the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after buying an additional 10,863 shares during the last quarter. Finally, Symmetry Partners LLC purchased a new position in shares of UiPath in the fourth quarter worth approximately $205,000. Hedge funds and other institutional investors own 59.04% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.